We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$5.45B
AUM Growth
+$30.2M
Cap. Flow
+$53.1M
Cap. Flow %
0.97%
Top 10 Hldgs %
47.61%
Holding
95
New
15
Increased
22
Reduced
33
Closed
14

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$199M
2
OSH
Oak Street Health, Inc.
OSH
+$119M
3
KYMR icon
Kymera Therapeutics
KYMR
+$83.4M
4
ANNX icon
Annexon
ANNX
+$80.8M
5
KLRS
Kalaris Therapeutics
KLRS
+$69.3M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$162M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$157M
3
BNTX icon
BioNTech
BNTX
+$132M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$64.2M
5
CYRX icon
CryoPort
CYRX
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 92.54%
2 Financials 0.5%
3 Technology 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLQT icon
51
SelectQuote
SLQT
$127M
$27.4M 0.5%
1,355,304
+858,432
+173% +$17.9M
TCDA
52
DELISTED
Tricida, Inc. Common Stock
TCDA
$25.9M 0.48%
2,858,415
+739,415
+35% +$10.8M
LMNX
53
DELISTED
Luminex Corp
LMNX
$24M 0.44%
914,107
-3,800
-0.4% -$117K
EIDX
54
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$23.6M 0.43%
466,205
-127,637
-21% -$5.74M
IMTX icon
55
Immatics
IMTX
$1.31B
$22.6M 0.41%
+2,130,000
New +$22.4M
ARDX icon
56
Ardelyx
ARDX
$1.28B
$18.4M 0.34%
3,514,100
– –
HOOK
57
DELISTED
HOOKIPA Pharma
HOOK
$17.5M 0.32%
184,290
-1,771
-1% -$181K
CTSO icon
58
Cytosorbents Corp
CTSO
$22.6M
$16.8M 0.31%
+2,101,131
New +$19M
ALXO icon
59
ALX Oncology
ALXO
$283M
$15.4M 0.28%
+407,400
New +$16M
CABA icon
60
Cabaletta Bio
CABA
$461M
$15M 0.28%
1,386,584
-39,312
-3% -$452K
PROF
61
Profound Medical
PROF
$249M
$14.6M 0.27%
825,000
+425,000
+106% +$6.75M
XERS icon
62
Xeris Biopharma Holdings
XERS
$1.52B
$14.2M 0.26%
2,397,441
– –
PAND
63
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$12.8M 0.24%
+1,119,600
New +$19.1M
ITMR
64
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$12.7M 0.23%
625,000
– –
CBAY
65
DELISTED
Cymabay Therapeutics
CBAY
$12.4M 0.23%
1,719,247
+44,800
+3% +$240K
FSDC
66
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$11.2M 0.21%
+1,000,000
New +$10.7M
GDRX icon
67
GoodRx Holdings
GDRX
$1.06B
$11.1M 0.2%
+200,000
New +$10.6M
STXS icon
68
Stereotaxis
STXS
$154M
$11.1M 0.2%
3,103,327
– –
DVAX
69
DELISTED
Dynavax Technologies
DVAX
$11M 0.2%
2,548,620
-2,513,480
-50% -$17.9M
NVTA
70
DELISTED
Invitae Corporation
NVTA
$8.45M 0.16%
195,003
-236,097
-55% -$8.06M
GRTS
71
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$8.11M 0.15%
3,059,794
-5,200
-0.2% -$19.3K
AYLA
72
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$7.85M 0.14%
666,666
– –
IMVT icon
73
Immunovant
IMVT
$8.27B
$4.26M 0.08%
120,940
-479,060
-80% -$14.4M
OM icon
74
Outset Medical
OM
$77.9M
$3.5M 0.06%
+4,667
New +$3.83M
SYRS
75
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.88M 0.03%
21,229
– –
1 2
3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2020 Portfolio in Review

As of Q3 2020, Redmile Group held 95 positions worth $5.45B, up 0.56% from $5.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q3 2020 filing shows 15 new, 22 increased, 33 reduced and 14 closed positions. Its largest new stake was Gilead Sciences: 2,869,962 shares worth $181M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $162M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

  • Redmile Group's largest Q3 2020 buy was Gilead Sciences: 2,869,962 shares worth $181M.
  • Redmile Group added most to Akero Therapeutics in Q3 2020, an estimated $67.9M increase.
  • Redmile Group's biggest Q3 2020 reduction was BioNTech, cutting an estimated $132M.
  • Redmile Group fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $162M.
  • Redmile Group's ten largest holdings make up 48% of its $5.45B portfolio in Q3 2020.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2020.
  • Redmile Group's portfolio value rose 0.56% quarter-over-quarter to $5.45B.

Based on Redmile Group's 13F filing for Q3 2020, filed 16 Nov 2020.